gh509
Metabolic Dysfunction-Associated Steatotic Liver Disease
Explore 131 assets in Metabolic Dysfunction-Associated Steatotic Liver Disease →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
1Globe Biomedical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05784779CT.gov Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| gh509 (this asset) | 1Globe Biomedical Co., Ltd. | P1/2 | CC · 45 |
| Dapagliflozin | Post Graduate Institute of Medical Education and Research, Chandigarh | P4 | BBB |
| Exenatide | Fudan University | P4 | BBB |
| Metformin | Xiqiao Zhou | P4 | BBB |
| Empagliflozin | Justin Ryder | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Tirzepatide | Regeneron Pharmaceuticals | P3 | BBB |
| Clesacostat | Columbia University | P2 | BB |
| Ervogastat | Pfizer | P2 | BB |
+42 more in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort
Other indications for gh509
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. gh509 in Metabolic Dysfunction-Associated Steatotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gh509-metabolic-dysfunction-associated-steatotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →